Urovant’s Vibegron Faces Tough Commercial Climb Despite Phase III Success

Roivant subsidiary thinks EMPOWUR data would position the drug as best-in-class in overactive bladder, but investors responded to the data with a clear thumbs-down.

Petri dish

Urovant Sciences Ltd. believes it has the data in hand to support a 2020 FDA filing for its overactive bladder drug vibegron, with the EMPOWUR trial hitting on all endpoints versus placebo, but underperforming against the generic anticholinergic tolterodine leaves it in a tricky commercial situation – and investors are expressing doubts.

On a March 19 investor call to outline the data, Urovant said vibegron should offer a quicker onset of action...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category